Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies

SRPT plans FDA filings to convert its exon-skipping therapies Amondys 45 and Vyondys 53 from accelerated to full approvals. The filings come despite a missed endpoint in a confirmatory study — the company will leverage new data to support approval, creating a binary regulatory outcome that could move the stock depending on FDA interpretation.

Analysis

SRPT plans FDA filings to convert its exon-skipping therapies Amondys 45 and Vyondys 53 from accelerated to full approvals. The filings come despite a missed endpoint in a confirmatory study — the company will leverage new data to support approval, creating a binary regulatory outcome that could move the stock depending on FDA interpretation.